XML 36 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
Organization and Significant Accounting Policies - Additional Information (Detail) - USD ($)
6 Months Ended
Nov. 18, 2016
Mar. 31, 2017
Mar. 31, 2016
Nov. 29, 2016
Sep. 30, 2016
Sep. 30, 2015
Schedule Of Investments [Line Items]            
Percentage of workforce reduced due to discontinued clinical program       30.00%    
Cash and cash equivalents   $ 61,718,971 $ 50,300,847   $ 85,366,448 $ 81,214,354
Short term investments   24,910,492        
Net increase (decrease) in cash   (23,647,477) (30,913,507)      
Cash outflows related to operating activities excluding upfront payment from Amgen   (34,300,000)        
Cash outflow from investments in commercial bonds   24,846,105        
Capital expenditures   6,653,158 500,634      
Proceeds from the issuance of common stock   12,691,937 $ 25,544      
Restricted Cash   0     0  
Short-term investment, gross unrealized losses   130,319        
Fair value   24,780,173        
Investments         0  
Fair value of contingent consideration obligation due to discontinuation of clinical trials   0     $ 0  
Corporate Bonds            
Schedule Of Investments [Line Items]            
Short term investments   24,910,492        
Short-term investment, gross unrealized losses   130,319        
Short-term investment, gross unrealized gain   0        
Maximum            
Schedule Of Investments [Line Items]            
Amount insured in FDIC per account   $ 250,000        
Property, Plant and Equipment, Useful Life   7 years        
Minimum            
Schedule Of Investments [Line Items]            
Property, Plant and Equipment, Useful Life   3 years        
Amgen            
Schedule Of Investments [Line Items]            
Proceeds from upfront payments and equity investments   $ 42,500,000        
Amgen | Common Stock Purchase Agreement            
Schedule Of Investments [Line Items]            
Proceeds from the issuance of common stock $ 12,500,000          
Amgen | ARO-LPA Agreement            
Schedule Of Investments [Line Items]            
Common stock issued 1,745,810          
Upfront payment $ 30,000,000          
Amgen | ARO-LPA Agreement | Common Stock Purchase Agreement            
Schedule Of Investments [Line Items]            
Common stock issued 1,745,810